title: Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Kaminski
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology; D010091:Oximes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011728:Pyridones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; D013792:Thalidomide; C467566:pomalidomide; C561627:dabrafenib